Slide 1: Investor Presentation Summer 2026
Summer 2026 Investor Presentation @IZOTROPIC WWW.IZOCORP.COM in @IZOTROPICCORP OTCQB: IZOZF | CSE: IZO
Slide 2: Forward-Looking Statements
a wr This document including links to press releases, presentations, fact sheets, and/or corporate materials including audio and video files either linked or imbedded, may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections,
Slide 3: Izotropic is the only publicly traded company commercializing a dedicated Breast CT platform
Izotropic is the only publicly traded company commercializing a dedicated Breast CT imaging platform, targeting unmet needs in breast cancer care. IzoView is a fully engineered, pre-commercial medical imaging device designed to overcome the limitations of mammography, DBT, ultrasound, and MRI, parti
Slide 4: Breast cancer is the most commonly diagnosed cancer in women
Breast cancer is the most commonly diagnosed cancer in women globally, with 2.3M+ new cases/year'. 315,000+ new cases expected in the U.S. in 2025”. Current technologies fail 50%+ of women with dense breasts’. U.S. regulatory mandates for breast density disclosure in mammography reports are now in e
Slide 5: Breast Imaging is a High-Growth, High-Need Market
GLOBAL $7.2B Breast Imaging is a High-Growth, High-Need Market. * Global breast imaging device market to grow from $5.4B in 2024 to $8.7B in 2030 (CAGR 8.25%). ¢ U.S. market projected to reach $1.55B by 2030? (CAGR 7.57%). ¢ Dense breast patients represent ~50% of women- a structurally underserved s
Slide 6: Mammography & Digital Breast Tomosynthesis (DBT)
Mammography & Digital Breast Tomosynthesis (DBT) Mammography misses ~20% of cancers present at the time of screening’. Compression-based 2D imaging (mammography and digital breast tomosynthesis) can hide breast cancers in dense tissue, as both dense tissue and cancers appear white on imaging. MRI, w
Slide 7: New Breast CT
ew Breast CT No Compression. No delays. JustAnswers. Purpose-built CT imaging system delivering true 3D breast images in ~10 seconds- without compression or breast handling. Fully self-shielded radiation system, installable in standard rooms, including outpatient clinics and mobile units. Spatial re
Slide 8: Mammography vs CE-Breast CT
MAMMOGRAPHY CE-BREAST CT 2D TRUE 3D, 360° x1 BREAST CT IMAGE SLICE Alll images are of the same breast
Slide 9: Complete funding to execute next phase of commercialization
Complete funding to execute next phase of commercialization plans. Announce hospital partners for FDA clinical study sites and IzoView clinical research locations. Build, ship, and install lzoView devices at partner hospitals. Initiate clinical study, image first patients. Announce new product devel
Slide 10: Comparable imaging companies: Hologic, Nano-X, Butterfly, iCAD, Lantheus
HOLOGIC NASDAQ: HOLX {INU NANO X@D Ee pen Teg iC A BD) Naspaa: icaD peste ane 225 NYSE: BLFY 4 LANTHEUS BRED XeR EN Trading around $65/share, Hologic transformed breast cancer screening by being the first to commercialize digital breast tomosynthesis (DBT), taking digital mammography from 2D to 15-d
Slide 11: Links
Links Website Videos News Team Podcast BreastCT.com 11
Slide 12: Izotropic: Advanced Imaging. Accessible Care.
ww IZOTROPIC »yCORPOR AT ean <a Advanced Imaging. Accessible Care. WWW.IZOCORP.COM ir@izocorp.com | info@izocorp.com 7 [CQB: IZOZF | CSE: 1ZO 1-833-IZO-CORP